Citigroup
JAZZ icon

Citigroup’s Jazz Pharmaceuticals JAZZ Stock Holding History

Citigroup’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,000
Closed -$248K – 5777
2025
Q1 		$248K Buy
+2,000
New +$261K ﹤0.01% 4073
2021
Q1 		– Sell
-6,500
Closed -$1.07M – 6840
2020
Q4 		$1.07M Sell
6,500
-28,500
-81% -$4.24M ﹤0.01% 3475
2020
Q3 		$4.99M Sell
35,000
-7,500
-18% -$930K ﹤0.01% 1888
2020
Q2 		$4.69M Sell
42,500
-13,000
-23% -$1.44M ﹤0.01% 1923
2020
Q1 		$5.54M Buy
55,500
+5,600
+11% +$724K 0.01% 1578
2019
Q4 		$7.45M Buy
49,900
+3,200
+7% +$435K 0.01% 1710
2019
Q3 		$5.98M Buy
46,700
+300
+0.6% +$40.2K ﹤0.01% 1780
2019
Q2 		$6.62M Buy
46,400
+12,600
+37% +$1.69M 0.01% 1740
2019
Q1 		$4.83M Sell
33,800
-3,100
-8% -$404K ﹤0.01% 1821
2018
Q4 		$4.57M Buy
36,900
+18,400
+99% +$2.73M ﹤0.01% 1889
2018
Q3 		$3.11M Buy
18,500
+700
+4% +$120K ﹤0.01% 2313
2018
Q2 		$3.07M Buy
17,800
+1,800
+11% +$294K ﹤0.01% 2299
2018
Q1 		$2.42M Sell
16,000
-600
-4% -$88K ﹤0.01% 2437
2017
Q4 		$2.23M Buy
16,600
+6,800
+69% +$943K ﹤0.01% 2567
2017
Q3 		$1.43M Sell
9,800
-27,800
-74% -$4.2M ﹤0.01% 3005
2017
Q2 		$5.85M Buy
37,600
+17,200
+84% +$2.63M 0.01% 1575
2017
Q1 		$2.96M Sell
20,400
-20,900
-51% -$2.72M ﹤0.01% 2106
2016
Q4 		$4.5M Buy
41,300
+15,200
+58% +$1.69M ﹤0.01% 1950
2016
Q3 		$3.17M Buy
26,100
+15,900
+156% +$2.14M ﹤0.01% 2084
2016
Q2 		$1.44M Sell
10,200
-9,100
-47% -$1.34M ﹤0.01% 2597
2016
Q1 		$2.52M Buy
19,300
+6,800
+54% +$846K ﹤0.01% 2227
2015
Q4 		$1.76M Buy
12,500
+5,500
+79% +$762K ﹤0.01% 2581
2015
Q3 		$930K Buy
7,000
+4,500
+180% +$775K ﹤0.01% 3155
2015
Q2 		$440K Buy
2,500
+2,000
+400% +$359K ﹤0.01% 3818
2015
Q1 		$86K Buy
+500
New +$85.8K ﹤0.01% 5134
2014
Q4 		– Sell
-71,400
Closed -$11.5M – 7208
2014
Q3 		$11.5M Buy
+71,400
New +$11M 0.01% 1180

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Citigroup's JAZZ Position: Q1 2026 in Review

Citigroup increased its Jazz Pharmaceuticals (JAZZ) stake by 137% in Q1 2026, buying an estimated $12.7M and bringing the position to 125,348 shares worth $23.7M. The position accounts for 0.01% of the portfolio, ranked #975.

Citigroup first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $24.7M in Q3 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Citigroup held 125,348 shares of Jazz Pharmaceuticals worth $23.7M as of Q1 2026.
  • Citigroup bought 72,543 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
  • Jazz Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #975 holding.
  • Citigroup first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Jazz Pharmaceuticals position peaked at $24.7M in Q3 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.